Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 May;59(5):359–367. doi: 10.1136/ard.59.5.359

Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele

P Vlachoyiannopoulo 1, U Dafni 1, I Pakas 1, M Spyropoulou-Vlach 1, C Stavropoulos-Giok 1, H Moutsopoulos 1
PMCID: PMC1753131  PMID: 10784518

Abstract

OBJECTIVE—Description of Greek patients with scleroderma with reference to (a) major organ disease, (b) autoantibodies, (c) survival rate, and (d) HLA associations.
METHODS—The clinical files of 254 patients were analysed retrospectively and a standardised clinical chart was completed with age at disease onset, sex, date of first and last visit, clinical and serological findings, organs affected, reasons for death, and HLA class II alleles. HLA class II alleles (DRB1, DQA1, DQB1, DPB1) were determined by polymerase chain reaction amplification using oligopeptide probes. DNA was extracted from 98 patients and 130 Greek controls.
RESULTS—124 patients (49%) had limited systemic sclerosis (lSSc), 114 (45%) had diffuse systemic sclerosis (dSSc), and 16 (6%) had overlap syndromes. Patients with dSSc, compared with lSSc, were characterised by a higher prevalence of lung disease (p=0.0011), oesophageal, heart, and peripheral vessel disease (p=0.027, p=0.0025, and p=0.012, respectively). Anticentromere antibodies (ACA) occurred exclusively in lSSc (34%), whereas antibodies to topoisomerase I (anti-topo I) were associated with dSSc (p<0.0001). Anti-topo I were associated with interstitial pulmonary fibrosis, oesophageal and peripheral vessel disease (p=0.028, p=0.012, and p=0.01, respectively). The HLA-DRB1*1104 allele was associated with the disease (p<0.0001) and anti-topo I (p<0.001), whereas it was not associated with ACA serum reactivity (p<0.001). Renal disease occurred in 4% of patients with SSc. The estimated survival probability for this cohort of patients with SSc, four years after the first visit, is 94.8%.
CONCLUSION—SSc among Greek subjects has the same pattern of organ disease as in other white populations. However, the prevalence of kidney disease is low. The HLA class II DRB1*1104 allele is associated with the disease, with anti-topo I, and not associated with ACA serum reactivity.



Full Text

The Full Text of this article is available as a PDF (147.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Estimated survival curves in patients with scleroderma and controls matched for age and sex (general population).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol. 1995 Nov;22(11):2100–2102. [PubMed] [Google Scholar]
  2. Aeschlimann A., Meyer O., Bourgeois P., Haim T., Belmatoug N., Palazzo E., Kahn M. F. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis. 1989 Dec;48(12):992–997. doi: 10.1136/ard.48.12.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Altman R. D., Medsger T. A., Jr, Bloch D. A., Michel B. A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991 Apr;34(4):403–413. doi: 10.1002/art.1780340405. [DOI] [PubMed] [Google Scholar]
  4. Bennett R., Bluestone R., Holt P. J., Bywaters E. G. Survival in scleroderma. Ann Rheum Dis. 1971 Nov;30(6):581–588. doi: 10.1136/ard.30.6.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Briggs D. C., Vaughan R. W., Welsh K. I., Myers A., duBois R. M., Black C. M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet. 1991 Sep 14;338(8768):661–662. doi: 10.1016/0140-6736(91)91235-m. [DOI] [PubMed] [Google Scholar]
  6. Briggs D., Stephens C., Vaughan R., Welsh K., Black C. A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum. 1993 Jul;36(7):943–954. doi: 10.1002/art.1780360711. [DOI] [PubMed] [Google Scholar]
  7. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol. 1996 Nov;35(11):1122–1126. doi: 10.1093/rheumatology/35.11.1122. [DOI] [PubMed] [Google Scholar]
  8. Catoggio L. J., Bernstein R. M., Black C. M., Hughes G. R., Maddison P. J. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis. 1983 Feb;42(1):23–27. doi: 10.1136/ard.42.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Englert H., Small-McMahon J., Davis K., O'Connor H., Chambers P., Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust N Z J Med. 1999 Feb;29(1):42–50. doi: 10.1111/j.1445-5994.1999.tb01587.x. [DOI] [PubMed] [Google Scholar]
  10. Fanning G. C., Welsh K. I., Bunn C., Du Bois R., Black C. M. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol. 1998 Feb;37(2):201–207. doi: 10.1093/rheumatology/37.2.201. [DOI] [PubMed] [Google Scholar]
  11. Fritzler M. J., Kinsella T. D. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980 Oct;69(4):520–526. doi: 10.1016/0002-9343(80)90462-3. [DOI] [PubMed] [Google Scholar]
  12. Genth E., Mierau R., Genetzky P., von Mühlen C. A., Kaufmann S., von Wilmowsky H., Meurer M., Krieg T., Pollmann H. J., Hartl P. W. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990 May;33(5):657–665. doi: 10.1002/art.1780330508. [DOI] [PubMed] [Google Scholar]
  13. Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986 Oct;13(5):911–916. [PubMed] [Google Scholar]
  14. Gladman D. D., Keystone E. C., Baron M., Lee P., Cane D., Mervert H. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum. 1981 Jun;24(6):854–856. doi: 10.1002/art.1780240614. [DOI] [PubMed] [Google Scholar]
  15. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998 Nov;57(11):682–686. doi: 10.1136/ard.57.11.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jacobsen S., Halberg P., Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma) Br J Rheumatol. 1998 Jul;37(7):750–755. doi: 10.1093/rheumatology/37.7.750. [DOI] [PubMed] [Google Scholar]
  17. Krishnamurthy V., Porkodi R., Ramakrishnan S., Rajendran C. P., Madhavan R., Achuthan K., Parthiban M., Chandrasekaran A. N. Progressive systemic sclerosis in south India. J Assoc Physicians India. 1991 Mar;39(3):254–257. [PubMed] [Google Scholar]
  18. Kuwana M., Kaburaki J., Arnett F. C., Howard R. F., Medsger T. A., Jr, Wright T. M. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum. 1999 Mar;42(3):465–474. doi: 10.1002/1529-0131(199904)42:3<465::AID-ANR11>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  19. Kuwana M., Kaburaki J., Okano Y., Inoko H., Tsuji K. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest. 1993 Sep;92(3):1296–1301. doi: 10.1172/JCI116703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kuwana M., Kaburaki J., Okano Y., Tojo T., Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994 Jan;37(1):75–83. doi: 10.1002/art.1780370111. [DOI] [PubMed] [Google Scholar]
  21. Kuwana M., Okano Y., Kaburaki J., Inoko H. HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Ann Rheum Dis. 1995 Dec;54(12):983–987. doi: 10.1136/ard.54.12.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Langevitz P., Buskila D., Gladman D. D., Darlington G. A., Farewell V. T., Lee P. HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. Br J Rheumatol. 1992 Sep;31(9):609–613. doi: 10.1093/rheumatology/31.9.609. [DOI] [PubMed] [Google Scholar]
  23. LeRoy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed] [Google Scholar]
  24. Lee P., Langevitz P., Alderdice C. A., Aubrey M., Baer P. A., Baron M., Buskila D., Dutz J. P., Khostanteen I., Piper S. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139–148. [PubMed] [Google Scholar]
  25. Livingston J. Z., Scott T. E., Wigley F. M., Anhalt G. J., Bias W. B., McLean R. H., Hochberg M. C. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol. 1987 Jun;14(3):512–518. [PubMed] [Google Scholar]
  26. Luderschmidt C., Scholz S., Mehlhaff E., König G., Albert E. Association of progressive systemic scleroderma to several HLA-B and HLA-DR alleles. Arch Dermatol. 1987 Sep;123(9):1188–1191. [PubMed] [Google Scholar]
  27. Manoussakis M. N., Constantopoulos S. H., Gharavi A. E., Moutsopoulos H. M. Pulmonary involvement in systemic sclerosis. Association with anti-Scl 70 antibody and digital pitting. Chest. 1987 Sep;92(3):509–513. doi: 10.1378/chest.92.3.509. [DOI] [PubMed] [Google Scholar]
  28. Masi A. T., D'Angelo W. A. Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore. Ann Intern Med. 1967 May;66(5):870–883. doi: 10.7326/0003-4819-66-5-870. [DOI] [PubMed] [Google Scholar]
  29. McNeilage L. J., Youngchaiyud U., Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989 Jan;32(1):54–60. doi: 10.1002/anr.1780320109. [DOI] [PubMed] [Google Scholar]
  30. Medsger T. A., Jr, Masi A. T. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med. 1971 May;74(5):714–721. doi: 10.7326/0003-4819-74-5-714. [DOI] [PubMed] [Google Scholar]
  31. Medsger T. A., Jr, Masi A. T., Rodnan G. P., Benedek T. G., Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971 Sep;75(3):369–376. doi: 10.7326/0003-4819-75-3-369. [DOI] [PubMed] [Google Scholar]
  32. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nevinny-Stickel C., Bettinotti M. D., Andreas A., Hinzpeter M., Mühlegger K., Schmitz G., Albert E. D. Nonradioactive HLA class II typing using polymerase chain reaction and digoxigenin-11-2'-3'-dideoxy-uridinetriphosphate-labeled oligonucleotide probes. Hum Immunol. 1991 May;31(1):7–13. doi: 10.1016/0198-8859(91)90042-8. [DOI] [PubMed] [Google Scholar]
  34. Nishioka K., Katayama I., Kondo H., Shinkai H., Ueki H., Tamaki K., Takehara K., Tajima S., Maeda M., Hayashi S. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol. 1996 Oct;23(10):677–682. doi: 10.1111/j.1346-8138.1996.tb02680.x. [DOI] [PubMed] [Google Scholar]
  35. Ochs R. L., Lischwe M. A., Spohn W. H., Busch H. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell. 1985;54(2):123–133. doi: 10.1111/j.1768-322x.1985.tb00387.x. [DOI] [PubMed] [Google Scholar]
  36. Okano Y., Steen V. D., Medsger T. A., Jr Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum. 1992 Jan;35(1):95–100. doi: 10.1002/art.1780350114. [DOI] [PubMed] [Google Scholar]
  37. Parker K. A., Steitz J. A. Structural analysis of the human U3 ribonucleoprotein particle reveal a conserved sequence available for base pairing with pre-rRNA. Mol Cell Biol. 1987 Aug;7(8):2899–2913. doi: 10.1128/mcb.7.8.2899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pudifin D. J., Dinnematin H., Duursma J. Antinuclear antibodies in systemic sclerosis. Clinical and ethnic associations. S Afr Med J. 1991 Nov 2;80(9):438–440. [PubMed] [Google Scholar]
  39. Reimer G., Steen V. D., Penning C. A., Medsger T. A., Jr, Tan E. M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum. 1988 Apr;31(4):525–532. doi: 10.1002/art.1780310409. [DOI] [PubMed] [Google Scholar]
  40. Reveille J. D., Durban E., Goldstein R., Moreda R., Arnett F. C. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum. 1992 Feb;35(2):216–218. doi: 10.1002/art.1780350215. [DOI] [PubMed] [Google Scholar]
  41. Reveille J. D., Durban E., MacLeod-St Clair M. J., Goldstein R., Moreda R., Altman R. D., Arnett F. C. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest. 1992 Sep;90(3):973–980. doi: 10.1172/JCI115974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Reveille J. D. Molecular genetics of systemic sclerosis. Curr Opin Rheumatol. 1993 Nov;5(6):753–759. doi: 10.1097/00002281-199305060-00010. [DOI] [PubMed] [Google Scholar]
  43. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  44. Satoh M., Akizuki M., Kuwana M., Mimori T., Yamagata H., Yoshida S., Homma M., Yamamoto T., Sasazuki T. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. J Rheumatol. 1994 Jan;21(1):111–114. [PubMed] [Google Scholar]
  45. Simeon C. P., Armadans L., Fonollosa V., Vilardell M., Candell J., Tolosa C., Mearin F., Rodrigo M. J., Solans R., Lima J. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis. 1997 Dec;56(12):723–728. doi: 10.1136/ard.56.12.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Simeón C. P., Castro-Guardiola A., Fonollosa V., Armadans L., Clemente C., Solans R., Pérez-Bocanegra C., Lima J., Vilardell M. Systemic sclerosis in men: clinical and immunological differences. Br J Rheumatol. 1996 Sep;35(9):910–911. doi: 10.1093/rheumatology/35.9.910. [DOI] [PubMed] [Google Scholar]
  47. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  48. Steen V. D., Ziegler G. L., Rodnan G. P., Medsger T. A., Jr Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984 Feb;27(2):125–131. doi: 10.1002/art.1780270202. [DOI] [PubMed] [Google Scholar]
  49. TUFFANELLI D. L., WINKELMANN R. K. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol. 1961 Sep;84:359–371. doi: 10.1001/archderm.1961.01580150005001. [DOI] [PubMed] [Google Scholar]
  50. Vlachoyiannopoulos P. G., Karassa F. B., Karakostas K. X., Drosos A. A., Moutsopoulos H. M. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus. 1993 Oct;2(5):303–312. doi: 10.1177/096120339300200505. [DOI] [PubMed] [Google Scholar]
  51. Weiner E. S., Earnshaw W. C., Senécal J. L., Bordwell B., Johnson P., Rothfield N. F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988 Mar;31(3):378–385. doi: 10.1002/art.1780310309. [DOI] [PubMed] [Google Scholar]
  52. Whiteside T. L., Medsger T. A., Jr, Rodnan G. P. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1983 Feb;10(1):128–131. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES